About Synchrogenix
Synchrogenix is a Technology company based in Wilmington (United States) founded in 1986, and was acquired by Certara in April 2014. It offers medical and regulatory writing services (including an AI assisted medical writing service). It operates in the Technology and Healthcare sectors. Synchrogenix has completed 1 acquisition, including ClinGenuity. Synchrogenix offers products and services including Phoenix, Pinnacle 21, GlobalSubmit, and Simcyp. Its focus areas include Biopharma Outsourcing, Consulting, Regulatory Affairs and High Tech. Its competitors include ProPharma Group, Validant and Technical Safety Services; 1 of its 3 listed competitors has raised funding.
Company details
Synchrogenix, a Certara company, offers regulatory writing services to the pharma, biotech and medical device companies globally. The company was bought by Arsenal Capital Partners, a PE firm in 2014 and merged with Certara, a global drug development and drug safety consultancy. In January 2015, Synchrogenix acquired ClinGenuity, which the company claims is the only AI-assisted medical writing service in the pharma industry. At the heart of their AI based offering is a SaaS based AI, natural-language processing engine that is capable of automating first drafts of regulatory documents (Study Report Writer) and redacting private and personal information in hours (ClinGenuity Redaction Management Service). The company claims that its writers are conversant with the industry guidelines in the International Council of Harmonisation (ICH) and the International Committee of Medical Journal Editors (ICMJE). The company claims to have supported over 50 drug applications over the recent years.
- Headquarters Wilmington, United States
- Stage Acquired
- SectorsTechnologyHealthcare
- Phone•••• ••••
- Website synchrogenix.com
- Social LinkedIn X
- Acquired by Certara (Apr 2014)
- Investors
- Investments & Acquisitions
- Acquired byCertara
(Apr 2014)
Products & Services of Synchrogenix
Synchrogenix offers a comprehensive portfolio of products and services, including Phoenix, Pinnacle 21, GlobalSubmit, and Simcyp.
Tool for PK, PD, and toxicokinetic analysis in drug development.
Platform for data standardization and validation in clinical trials.
System for publishing and transmitting regulatory submissions.
Tool for predicting drug behavior in various populations.
Investors in Synchrogenix
Synchrogenix has secured backing from 1 investor. Prominent investors backing the company include Certara.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of a platform for in silico drug discovery and consulting services | 2008 | certara.com | Princeton, United States |
Investor details for Synchrogenix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Synchrogenix
19 people are tracked at Synchrogenix (10 in leadership, 8 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Max Kanevsky | Chief Technology Officer | Leadership |
Patrick F. Smith | President, Certara Drug Development Solutions | Leadership |
John E. Gallagher III | CFO | Leadership |
Daniel Corcoran | Chief Counsel | Leadership |
Rona Anhalt | Chief Human Resources Officer | Leadership |
William F. Feehery | CEO | Leadership |
Leif E. Pedersen | President & CCO | Leadership |
lucas Hixson | Director of Corporate Strategy | Leadership |
Robert Aspbury | President, Certara Scientific Software | Leadership |
Sheila Rocchio | Chief Marketing Officer | Leadership |
Stephen McLean | Director | Board & advisors |
James E. Cashman III | Chairman | Board & advisors |
Cynthia Collins | Director | Board & advisors |
Nancy Killefer | Director | Board & advisors |
David Spaight | Director | Board & advisors |
Matthew Walsh | Director | Board & advisors |
Rosemary Crane | Director | Board & advisors |
Eran Broshy | Director | Board & advisors |
Ron DiSantis | SVP, Corporate Development | Team |
Complete people profiles for Synchrogenix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Synchrogenix
Synchrogenix has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ClinGenuity.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
AI-assisted medical writing services are provided for pharmaceutical firms. | clingenuity.com | Cincinnati, United States | 2011 | Dec 2014 | •••• |
Complete acquisition details for Synchrogenix
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Synchrogenix
3 dated milestones of Synchrogenix across 28 years, from founding to its latest funding, stage changes and deals.
- Founded Synchrogenix is founded.
- Exit Acquired by Certara.
- Acquisition Acquires ClinGenuity.
Competitors of Synchrogenix
Synchrogenix has 3 listed competitors in our database, 1 of them funded. They include ProPharma Group, Validant and Technical Safety Services.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| propharmagroup.com | 2001 | Saint Paul, United States | 999 | Provider of regulatory compliance solutions to pharmaceutical, biotechnology and medical device | ||
| validant.com | 2005 | San Francisco, United States | $2.28M | Regulatory, compliance, and quality consulting for GxP lifecycles is provided. | ||
| techsafety.com | 1970 | Berkeley, United States | 71 | Healthcare instrumentation, medical gas systems, and related devices are manufactured. |
Detailed competitors of Synchrogenix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Natural Language & Voice AI
3 companies that operate in the same segment as Synchrogenix (Natural Language & Voice AI) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
OpenAI is engaged in developing advanced artificial intelligence technologies. | 2015 | San Francisco, California, United States | USD 58.07 B | 11,115 | ||
Enterprise AI models are developed and tuned for business integration. | 2022 | Palo Alto, California, United States | USD 1.53 B | 84 | ||
AI-generated music and lyrics are created on an online platform. | 2021 | Cambridge, Massachusetts, United States | USD 775 M | 497 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Synchrogenix
Complete news archive for Synchrogenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synchrogenix
Synchrogenix was founded in 1986.
Synchrogenix is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Synchrogenix, a Certara company, offers regulatory writing services to the pharma, biotech and medical device companies globally. The company was bought by Arsenal Capital Partners, a PE firm in 2014 and merged with Certara, a global drug development and drug safety consultancy. In January 2015, Synchrogenix acquired ClinGenuity, which the company claims is the only AI-assisted medical writing service in the pharma industry. At the heart of their AI based offering is a SaaS based AI, natural-language processing engine that is capable of automating first drafts of regulatory documents (Study Report Writer) and redacting private and personal information in hours (ClinGenuity Redaction Management Service). The company claims that its writers are conversant with the industry guidelines in the International Council of Harmonisation (ICH) and the International Committee of Medical Journal Editors (ICMJE). The company claims to have supported over 50 drug applications over the recent years.
Synchrogenix's top competitors include ProPharma Group, Validant and Technical Safety Services.
Synchrogenix offers Phoenix, Pinnacle 21, GlobalSubmit, and Simcyp.
Synchrogenix has made 1 acquisition, including ClinGenuity.
Synchrogenix has 1 investor. Key investors include Certara.
Yes. Synchrogenix was acquired by Certara in April 2014.